332
Views
9
CrossRef citations to date
0
Altmetric
Review

Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia

, , , , , & show all
Pages 601-611 | Received 05 Apr 2018, Accepted 28 Jun 2018, Published online: 18 Jul 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Cristina Bagacean, Ciprian Tomuleasa, Adrian Tempescul, Ravnit Grewal, Wesley H. Brooks, Christian Berthou & Yves Renaudineau. (2019) Apoptotic resistance in chronic lymphocytic leukemia and therapeutic perspectives. Critical Reviews in Clinical Laboratory Sciences 56:5, pages 321-332.
Read now

Articles from other publishers (8)

Andrea Visentin, Stefano Pravato, Francesca Castellani, Marta Campagnolo, Francesco Angotzi, Chiara Adele Cavarretta, Alessandro Cellini, Valeria Ruocco, Alessandro Salvalaggio, Alessandra Tedeschi, Livio Trentin & Chiara Briani. (2022) From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance. Cancers 14:6, pages 1562.
Crossref
Hye Na Kim, Heather Ogana, Vanessa Sanchez, Cydney Nichols & Yong-Mi Kim. 2022. PI3K and AKT Isoforms in Immunity. PI3K and AKT Isoforms in Immunity 393 407 .
Sanja Nabergoj, Tijana Markovič, Damjan Avsec, Martina Gobec, Helena Podgornik, Žiga Jakopin & Irena Mlinarič-Raščan. (2021) EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells. Biochemical Pharmacology 183, pages 114352.
Crossref
Chiara Briani, Andrea Visentin, Federica Cerri & Angelo Quattrini. (2020) From pathogenesis to personalized treatments of neuropathies in hematological malignancies. Journal of the Peripheral Nervous System 25:3, pages 212-221.
Crossref
Carmen D Herling, Kevin R Coombes, Axel Benner, Johannes Bloehdorn, Lynn L Barron, Zachary B Abrams, Tadeusz Majewski, Jolanta E Bondaruk, Jasmin Bahlo, Kirsten Fischer, Michael Hallek, Stephan Stilgenbauer, Bogdan A Czerniak, Christopher C Oakes, Alessandra Ferrajoli, Michael J Keating & Lynne V Abruzzo. (2019) Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. The Lancet Oncology 20:11, pages 1576-1586.
Crossref
Andrea Visentin, Marina Deodato, Francesca R. Mauro, Francesco Autore, Gianluigi Reda, Candida Vitale, Stefano Molica, Gian Matteo Rigolin, Francesco Piazza, Laura Cesini, Alessandra Tedeschi, Luca Laurenti, Ramona Cassin, Marta Coscia, Antonio Cuneo, Robin Foà, Gianpietro Semenzato & Livio Trentin. (2019) A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. Hematological Oncology 37:4, pages 508-512.
Crossref
Scott H. Watterson, Qingjie Liu, Myra Beaudoin Bertrand, Douglas G. Batt, Ling Li, Mark A. Pattoli, Stacey Skala, Lihong Cheng, Mary T. Obermeier, Robin Moore, Zheng Yang, Rodney Vickery, Paul A. Elzinga, Lorell Discenza, Celia D’Arienzo, Kathleen M. Gillooly, Tracy L. Taylor, Claudine Pulicicchio, Yifan Zhang, Elizabeth Heimrich, Kim W. McIntyre, Qian Ruan, Richard A. Westhouse, Ian M. Catlett, Naiyu Zheng, Charu Chaudhry, Jun Dai, Michael A. Galella, Andrew J. Tebben, Matt Pokross, Jianqing Li, Rulin Zhao, Daniel Smith, Richard Rampulla, Alban Allentoff, Michael A. Wallace, Arvind Mathur, Luisa Salter-Cid, John E. Macor, Percy H. Carter, Aberra Fura, James R. Burke & Joseph A. Tino. (2019) Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK). Journal of Medicinal Chemistry 62:7, pages 3228-3250.
Crossref
Vanessa Sanchez, Cydney Nichols, Hye Kim, Eun Gang & Yong-Mi Kim. (2019) Targeting PI3K Signaling in Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences 20:2, pages 412.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.